Key result
Once-daily oral LILRB4 modulation suppresses tumor growth and enhances immune activation in syngeneic colorectal models.
Small molecule modulation of LILRB4 (ILT3) restores antitumor immunity and suppresses tumor growth in vivo, supporting its potential as a nonbiologic cancer immunotherapy.
Supports oral small-molecule LILRB4 inhibition in preclinical models; leaves open clinical translation in cancer.
additionally demonstrated favorable pharmacokinetic and safety properties supporting oral in vivo administration. In immunocompetent CT26 syngeneic colorectal tumors, once-daily oral treatment significantly suppressed tumor growth and enhanced intratumoral immune activation. Collectively, these findings establish LILRB4 as a tractable target for direct small molecule immunomodulation and support therapeutic targeting of suppressive myeloid immune checkpoints for cancer using nonbiologic modalities.
No takes yet. Share an insight, caveat, or question.
Sm et al. (2026) studied Colorectal tumors. Small molecule modulation of LILRB4 (ILT3) was evaluated on Tumor growth and intratumoral immune activation. Once-daily oral small molecule modulation of LILRB4 significantly suppressed tumor growth and enhanced intratumoral immune activation in immunocompetent CT26 syngeneic colorectal tumors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: